Check Before You Invest : Ind-Swift Laboratories Ltd

Snapshot

Q.1 Which industry/sub-sector does Ind-Swift Laboratories Ltd belong to?

Ind-Swift Laboratories Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Ind-Swift Laboratories Ltd a good quality company?

Ind-Swift Laboratories Ltd is a average quality company, based on a somewhat consistent 10-year financial track record.

Q.3 Is Ind-Swift Laboratories Ltd undervalued or overvalued?

Ind-Swift Laboratories Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.

Q.4 Is Ind-Swift Laboratories Ltd a good buy now?

Ind-Swift Laboratories Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Ind-Swift Laboratories Ltd?

Ind-Swift Laboratories Ltd revenue growth is -55.2% for FY-2025, which is below its 5-year CAGR of -6.07%, indicating slower growth.

Q.2 Return on capital employed (ROCE) of Ind-Swift Laboratories Ltd?

Ind-Swift Laboratories Ltd Return on capital employed is 25.18% for FY-2025, which is above its 5-year historical median of 12.67%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 14%, indicating value creation.

Q.3 Return on Asset of Ind-Swift Laboratories Ltd?

Ind-Swift Laboratories Ltd Return on Asset is 20.9%, which is above its 5-year historical median of 2.42%, indicating improved asset utilization efficiency.

Q.4 Return on Equity (ROE) of Ind-Swift Laboratories Ltd?

Ind-Swift Laboratories Ltd Return on equity is 25.45% for FY-2025, which is above its 5-year historical median of 9.17%, indicating the business is making better use of its shareholders capital.

Q.5 Cash conversion cycle of Ind-Swift Laboratories Ltd?

Ind-Swift Laboratories Ltd Cash conversion cycle is 62 days, below its 5-year historical median of 208 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover	0.46	0.57
ROE	25.45	9.17
ROCE	25.18	12.67
Cash Conversion Cycle	62 days	208 days

Q.6 Gross Profit margin of Ind-Swift Laboratories Ltd?

Ind-Swift Laboratories Ltd Gross profit margin which is the profit after deduction of direct costs, is 11.6% for FY-2025, which is below its 5-year median of 14.1%, indicating decreasing margins.

Q.7 Operating Profit Margin of Ind-Swift Laboratories Ltd?

Ind-Swift Laboratories Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -2.35% for FY-2025, which is below its 5-year median of 20.18% indicating decreasing margins.

Q.8 Net Profit Margin of Ind-Swift Laboratories Ltd?

Ind-Swift Laboratories Ltd Net Profit Margin is 46.59% for FY-2025, is above with its 5-year median of 3.69%, indicating increasing margins.

	Current Level	5-year Historic Median
Gross Profit Margin	11.6	14.1
Operating Profit Margin	-2.35	20.18
Net Profit Margin	46.59	3.69

Q.9 Debt to Equity ratio of Ind-Swift Laboratories Ltd?

Ind-Swift Laboratories Ltd Debt-to-Equity ratio is 0.03, which is lower with the industry average of 0.27, indicating lower debt levels in the industry.

Q.10 Debt to cash flow from operations of Ind-Swift Laboratories Ltd?

Ind-Swift Laboratories Ltd Debt to cash flow from operations is -0.75, which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Ind-Swift Laboratories Ltd?

Promoters hold 42.99% of the Ind-Swift Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Ind-Swift Laboratories Ltd vs industry peers?

Ind-Swift Laboratories Ltd revenue CAGR is -6.07%, compared to the industry median CAGR of 8.30%, indicating slower growth and losing its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth	-55.2	8.3
Gross Profit Growth	-73.4	14.7
Operating Profit Growth	-105.2	11.4
Net Profit Growth	-38.8	NAN

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover	0.46	0.81
ROE	25.45	9.49
ROCE	25.18	11.91
Cash Conversion Cycle (days)	62.37	85

Valuation & price assessment

Q.1 Stock return of Ind-Swift Laboratories Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 12.9% based on the current price.

Q.2 What return has the stock given over the last decade?

	9Y	5Y	3Y	1Y
Share Price CAGR	12.9%	11.2%	26.1%	89.4%

Q.3 Valuation ratios of Ind-Swift Laboratories Ltd vs historical?

The current P/E is lower that its historical median.

Q.4 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	4.85	11.86	31.09
Price to Book	0.87	0.82	2.85
Price to Sales	2.01	0.53	2.79
EV to EBITDA	13.37	5.45	15.87

Check more companies

6. Wockhardt

7. Pfizer

8. Piramal Pharma

9. Acutaas Chemicals

10. Astrazeneca Pharma I

Check trending companies

1. Force Motors Ltd.

2. KEI Industries Ltd.

3. Aadhar Housing Finance Ltd.

4. State Bank Of India

5. Power Finance Corporation Ltd.